MA44085A - Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants - Google Patents
Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendantsInfo
- Publication number
- MA44085A MA44085A MA044085A MA44085A MA44085A MA 44085 A MA44085 A MA 44085A MA 044085 A MA044085 A MA 044085A MA 44085 A MA44085 A MA 44085A MA 44085 A MA44085 A MA 44085A
- Authority
- MA
- Morocco
- Prior art keywords
- diamino
- alkylamino
- bonded
- voltage
- sodium channels
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269648P | 2015-12-18 | 2015-12-18 | |
| US201662417040P | 2016-11-03 | 2016-11-03 | |
| US201662422182P | 2016-11-15 | 2016-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44085A true MA44085A (fr) | 2021-04-21 |
Family
ID=59057567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044085A MA44085A (fr) | 2015-12-18 | 2016-12-15 | Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10519147B2 (fr) |
| EP (1) | EP3389654B1 (fr) |
| JP (1) | JP2019502688A (fr) |
| KR (1) | KR20180096683A (fr) |
| CN (1) | CN109069489A (fr) |
| AU (1) | AU2016370677A1 (fr) |
| BR (1) | BR112018012408A2 (fr) |
| CA (1) | CA3008614A1 (fr) |
| MA (1) | MA44085A (fr) |
| WO (1) | WO2017106409A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3390374B1 (fr) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Composés diamine-arylsulfonamide à substitution hydroxyalkylamine et hydroxycycloalkylamine avec activité sélective des canaux sodiques sensibles à la tension |
| US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| HRP20250505T1 (hr) | 2016-05-20 | 2025-06-20 | Xenon Pharmaceuticals Inc. | Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva |
| AU2017347549A1 (en) | 2016-10-17 | 2019-05-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| ES2897998T3 (es) * | 2016-10-27 | 2022-03-03 | Bristol Myers Squibb Co | Inhibidores de la acilsulfonamida del NaV1.7 |
| US10968210B2 (en) | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| ES2967410T3 (es) | 2016-12-09 | 2024-04-30 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019191702A1 (fr) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| EP3891157A4 (fr) * | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension |
| CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1673357A2 (fr) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
| EP1995241B1 (fr) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibiteurs de canaux d'ion |
| PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| CA2950393A1 (fr) * | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques |
| WO2016009303A1 (fr) * | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 |
| EP3390374B1 (fr) * | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Composés diamine-arylsulfonamide à substitution hydroxyalkylamine et hydroxycycloalkylamine avec activité sélective des canaux sodiques sensibles à la tension |
| US10968210B2 (en) * | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
-
2016
- 2016-12-15 EP EP16876635.0A patent/EP3389654B1/fr active Active
- 2016-12-15 WO PCT/US2016/066765 patent/WO2017106409A1/fr not_active Ceased
- 2016-12-15 CA CA3008614A patent/CA3008614A1/fr not_active Abandoned
- 2016-12-15 MA MA044085A patent/MA44085A/fr unknown
- 2016-12-15 KR KR1020187020096A patent/KR20180096683A/ko not_active Withdrawn
- 2016-12-15 AU AU2016370677A patent/AU2016370677A1/en not_active Abandoned
- 2016-12-15 BR BR112018012408A patent/BR112018012408A2/pt not_active Application Discontinuation
- 2016-12-15 US US16/061,815 patent/US10519147B2/en active Active
- 2016-12-15 JP JP2018531237A patent/JP2019502688A/ja active Pending
- 2016-12-15 CN CN201680081253.3A patent/CN109069489A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10519147B2 (en) | 2019-12-31 |
| CN109069489A (zh) | 2018-12-21 |
| EP3389654A1 (fr) | 2018-10-24 |
| JP2019502688A (ja) | 2019-01-31 |
| WO2017106409A1 (fr) | 2017-06-22 |
| KR20180096683A (ko) | 2018-08-29 |
| AU2016370677A1 (en) | 2018-06-07 |
| EP3389654A4 (fr) | 2019-05-22 |
| EP3389654B1 (fr) | 2023-08-16 |
| US20180362518A1 (en) | 2018-12-20 |
| CA3008614A1 (fr) | 2017-06-22 |
| BR112018012408A2 (pt) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44085A (fr) | Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants | |
| EP3737672A4 (fr) | Composés benzamide | |
| MA40551A (fr) | Composés actifs envers des bromodomaines | |
| EP2770995A4 (fr) | Composés de benzoxazolinone ayant une activité sélective dans des canaux sodiques voltage-dépendants | |
| MA56008A (fr) | Composés et compositions pour traiter des états associés à une activité de nlrp | |
| MA42293A (fr) | Composés antibactériens | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| EP3484464A4 (fr) | Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective dans des canaux sodiques sensibles à la tension | |
| EP2911668A4 (fr) | Composés benzoxazolinone ayant une activité sélective dans les canaux sodiques potentiel-dépendants | |
| EP2964221A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine | |
| EP2950649A4 (fr) | Composés amine ayant une activité anti-inflammatoire, antifongique, antiparasitaire et anticancéreuse | |
| EP2964222A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
| EP3340844A4 (fr) | Mélangeur personnel amélioré | |
| EP2964220A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
| EP3317241A4 (fr) | Composés inhibiteurs thérapeutiques | |
| MA43155A (fr) | Composition de déblocage de nez congestionné présentant une activité antivirale | |
| EP2966327A4 (fr) | Structure perfectionnée de robinet à trois voies | |
| EP3728289A4 (fr) | Composés optimisés | |
| MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| EP3280445A4 (fr) | Thérapie génique pour prévenir les réactions à des allergènes | |
| EP3464336A4 (fr) | Composés | |
| EP3261631C0 (fr) | Inhibition de l'activité d'olig2 | |
| EP3405231A4 (fr) | Connecteurs à usage unique | |
| IL254792A0 (en) | Novel pyridinium compounds |